Novo Nordisk links next-gen obesity drug to 22% weight loss at Week 36, sending stock up 11%

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% jump in the Danish drugmaker’s share price in premarket trading.